The subsidised pricing structure of Drug Science’s medical cannabis registry, ‘T21’, is changing to a new model. Until now, T21 has operated at a £150 price cap on all prescriptions – a model that has remained in place since its launch over three years ago. This cap will now be replaced, and registered patients will instead receive a minimum of 5 percent discount on all cannabis-based medicines (CBMPs) included in the T21 formulary.
Replacing the price cap model means that costs of medication will be determined by each producer who partners with T21 and not by Drug Science. Our founding partners Khiron Life Sciences Corp, Cellen Health and JMCC Group have confirmed that they are not changing their existing pricing, and existing patients should not notice any difference in their prescription costs.
We want to express our gratitude to the T21 partners for their continued commitment to patient access during these financially trying times. And we can confirm that Lyphe Group will not be continuing the project after being a partner for two rewarding years. We’re especially grateful for their involvement and hard work in making T21 a success. For patients, this means that the Noidecs product range has been removed from the T21 Formulary, and its discount will no longer apply (however, patients prescribed Noidecs products can remain with T21 and continue to provide their data to the study).
Should patients require any further details on pricing, they should speak to their clinician. A full set of FAQs can be found below our announcement from last week (16th January).